ERBB2 and breast cancer: Additionally, triple-negative IBC patients (i.e., negative for ER, PR, and HER2) presented increased AGER expression (136.8 ± 6.8) compared to subjects with other BC phenotypes in non-IBC samples (87.7 ± 40.3) (p = 0.045).